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Abstract
By using disuccinimidyl suberate, we have covalently cross-
linked 1251-labeled somatomedin-C (Sm-C)/insulinlike growth
factor I to specific binding proteins in human plasma. In
unfractionated plasma samples from normal and acromegalic
donors, '251-Sm-C binding-protein complexes with relative mo-
lecular weights (Mr) of 160,000, 135,000, 110,000, 80,000,
50,000, 43,000-35,000, and 28,000-24,000 were consistently
observed. In contrast, the 43,000-35,000-mol wt species were
frequently the only specific complexes observed in hypopituitary
plasma and were consistently more intensely labeled in such
samples. Reduction of samples with ,B-mercaptoethanol did not
alter the electrophoretic pattern of these '25I-Sm-C binding-
protein complexes. All Sm-C binding proteins, with the excep-
tion of the 43,000-35,000-mol wt complex, were adsorbed by
concanavalin A-Sepharose. When acromegalic or normal plasma
was fractionated on a Sephadex G-200 column and affinity
labeled, the same complexes that were adsorbed by concanav-
alin A were found in fractions that eluted near the -y-globulin
peak. On the other hand, the 43,000-35,000-mol wt complex
consistently eluted in size-appropriate fractions near the albumin
peak. These data suggest that the growth hormone (GH)-
dependent Sm-C binding protein, represented by the 160,000-
mol wt complex, is in some way composed of smaller species,
i.e., the 135,000-, 110,000-, 80,000-, 50,000-, and 28,000-
24,000-mol wt complexes. Acid incubation of plasma prior to
Sephadex G-200 chromatography results in the elimination of
specific '25I-Sm-C binding-protein complexes which elute near
-globulin and a concurrent increase in the labeling intensity
of the 28,000-24,000-mol wt complexes. We speculate, there-
fore, that each of the GH-dependent Sm-C binding-protein
complexes represents an oligomer composed of 28,000-24,000-
mol wt protomers. The 43,000-35,000-mol wt species is not
dependent upon GH and appears to represent a different type
of Sm-C binding protein.
Introduction
The molecular weight of somatomedin-C/insulinlike growth
factor I (Sm-C/IGF-I)' is 7,649 (1, 2), but it circulates in the
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1. Abbreviations used in this paper: BS3, bis(sulfosuccinimidyl)suberate;
Con A, concanavalin A; DMS, dimethyl suberimidate; DSS, disucci-
blood at much higher relative molecular weights (Mr
- 150,000 and 40,000) because it is complexed with binding
proteins (3-15). The -y-globulin-sized (- 150,000 mol wt),
somatomedin binding protein is growth hormone (GH) depen-
dent and is associated with the majority of circulating soma-
tomedin (6-9, 11, 16-19). It is thought to be composed of at
least two subunits (8); however, neither its structure nor that
of the smaller (-40,000 mol wt) Sm-C binding protein is
known.
Virtually all published studies have approached the char-
acterization of plasma somatomedin binding proteins in one
or both of two ways: evaluation of the elution pattern of
radioactivity from gel filtration columns after incubation of
labeled somatomedin and serum (3-12, 14-16, 18-21), or
assessment of binding activity by activated charcoal separation
of free and bound labeled peptide after its incubation with
serum (3, 6, 9-13, 15, 16, 18, 19, 21). We have developed a
technique to affinity-label circulating Sm-C binding-proteins
using the cross-linking agent disuccinimidyl suberate (DSS)
(22, 23) and now report its utility in studies of these proteins
in postnatal human plasma. This technique utilizes sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis
(PAGE) to separate the covalently cross-linked '251-Sm-C bind-
ing-protein complexes, and hence provides greater resolution
of Sm-C binding moieties than has heretofore been available.
New insights resulting from this study have led us to propose
that the GH-dependent, y-globulin-sized plasma Sm-C binding
protein is an oligomer composed of identical subunits. The
apparent Mr of the '251-Sm-C monomer complex is 28,000-
24,000.
Methods
Plasma samples. All blood samples were collected between 0900 and
1200 h by venipuncture into EDTA vacutainers (Becton-Dickinson &
Co., Rutherford, NJ) from individuals on regular diets. They were
immediately chilled on ice, separated by centrifugation within 2 h, and
frozen at -20'C until use (usually within 4 wk). Immunoreactive Sm-
C was determined on each plasma sample by a modified (7, 20)
nonequilibrium technique (24). Studies of normal plasma were per-
formed on samples collected from healthy adult males. Acromegalic
plasma samples were obtained from a number of individuals, but all
the studies reported here represent samples obtained from a 12-yr-
old white boy whose diagnosis was based on a basal GH level of 11
ng/ml, a peak GH of 20 ng/ml 30 min after thyrotropin-releasing
hormone infusion, and plasma immunoreactive Sm-C concentrations
of between 8.1 and 11.2 U/ml. Transphenoidal exploration revealed
an adenoma 8 mm in diameter. Hypopituitary plasma was obtained
from a number of prepubertal children between the ages of 2-7/12
and 18-9/12 yr (four boys and four girls). All were significantly below
the 3rd centile for height (2.9-6.0 SD below 50th centile), had growth
nimidyl suberate; DTSSP, 3,3'-dithiobis(sulfosuccinimidyl propionate);
GH, growth hormone; hGH, human growth hormone; IGF-I, insulinlike
growth factor I; PAGE, polyacrylamide gel electrophoresis; Sm-C,
somatomedin-C.
1350 J. R. Wilkins and A. J. D'Ercole
J. Clin. Invest.
© The American Society for Clinical Investigation, Inc.
0021-9738/85/04/1350/09 $ 1.00
Volume 75, April 1985, 1350-1358
velocities of <4.00 cm/yr (1.9-3.7 cm/yr), lacked a significant GH
response to two different provocative stimuli (usually insulin-induced
hypoglycemia and arginine), and had basal plasma Sm-C concentrations
of <0.25 U/ml (0.03-0.23 U/ml). Collection of blood was approved
by the Committee for Protection of Human Subjects, University of
North Carolina at Chapel Hill.
Reagents. '25l-labeled somatomedin-C ('251I-Sm-C) had a specific
activity of 200 MCi/Mg and was judged by multiple criteria to be no
less than 90% pure (25). The '251-Sm-C was stored at -20'C in 2%
bovine serum albumin. For studies of binding specificity, purified Sm-
C was used. When an excess of Sm-C was required, partially purified
preparations obtained after isoelectrofocusing were used (25). Mono-
component porcine insulin (lots 615-07J-50) was a gift from Eli Lilly
Co (Indianapolis, IN). DSS, bis(sulfosuccinimidyl)suberate (BS3), sul-
fosuccinimidyl 644'-azido-2'-nitrophenylamino)hexandate (Sulfo-San-
pah), 3,3'-dithiobis(sulfosuccinimidyl propionate) (DTSSP), and di-
methyl suberimidate (DMS) were all purchased from Pierce Chemical
Co, Rockford, IL. All chemicals used were reagent grade.
Affinity-labeling technique. Aliquots of plasma (10 or 50 M1) diluted
1:10 in 0.05 M Na phosphate buffer (pH 7.4) were preincubated on
ice for 10-30 min in the presence of 250,000 cpm (110 fmol) of '25I-
Sm-C. Cross-linking of '251-Sm-C to plasma proteins was accomplished
by the addition of 10 Ml of 10 or 50 mM DSS dissolved in dimethyl
sulfoxide to give a final concentration of 1 mM DSS, followed by
incubation at room temperature for 10 min.
When 50 Ml of normal plasma dissolved in 0.5 ml of 0.05 M Na
phosphate buffer (pH 7.4) was incubated with as little as 5 ng of
unlabeled Sm-C in addition to '25I-Sm-C, labeling of specific Sm-C
binding proteins was significantly reduced. Incubation with 100 ng of
unlabeled Sm-C was sufficient to obliterate completely all specific
labeling, whereas as much as 1 mg of insulin had no effect. Labeled
bands were judged to be specific Sm-C binding proteins if they were
abolished as a result of incubation with an excess of unlabeled Sm-C
(25 ng/10 Ml plasma in a 1:10 dilution with buffer).
The parameters for incubation of '25I-Sm-C with plasma and the
cross-linking procedure were determined experimentally by altering
variables individually at first and later in concert to determine the
conditions that consistently resulted in intensely labeled, specific bands
and minimalized nonspecific labeling. The parameters studied were
the dilution of plasma (1:1, 1:5, 1:10, 1:20 and 1:50), time (0.5 min
to 18 h) of incubation, and concentration of DSS (0.25-5.0 mM), and
temperature of cross-linking (0, 4, and 22-24°C). >1:10 dilution of
whole plasma samples generally decreased the intensity of specifically
labeled bands; on the other hand, plasma dilutions of <1:10 dramatically
increased nonspecific labeling without an increase in the intensity of
specifically labeled bands. The time of incubation of '25I-Sm-C and
plasma at either 00 or 4°C did not alter results, but incubation at
22°-24°C increased nonspecific labeling. Concentrations of DSS be-
tween 0.5-1.0 mM maximized the intensity of specifically labeled
bands. Higher DSS concentrations consistently resulted in an increase
in nonspecific cross-linking and protein precipitation. The time allowed
for the reaction was not critical, because the cross-linking reaction goes
to completion in minutes. Plasma, rather than serum, was used in this
study because the Sm-C binding proteins appeared to be more stable
over time in plasma; however, no differences were observed when fresh
plasma and serum were compared. Collection of plasma in Aprotinin
5-10 TIU/ml (Sigma Chemical Co., St. Louis, MO) or 0.1 mM
phenylmethylsulfonyl fluoride did not alter results.
The cross-linking agents BS3, Sulfo-Sanpah, DTSSP, and DMS
were tested under similar experimental conditions to explore the
possibility that binding proteins could exist which were not affinity
labeled by DSS, but might be labeled when an alternate cross-linker
was used. Of those tested, BS3 and DTSSP were effective and produced
electrophoretic patterns of cross-linked '25I-Sm-C binding-protein com-
plexes identical to those generated by DSS.
PAGE and autoradiography. SDS-PAGE was performed on 7-15%
linear gradient 16 X 1 7-cm slab gels according to the method of Janis
et al. (26) with minor modifications. Gels were preelectrophoresed for
at least 2 h with a constant power of 10 W/gel before loading samples.
Electrophoresis was performed using the Tris-glycine buffer system of
Laemmli (27). Electrophoresis of samples was accomplished overnight
at room temperature with constant voltage of 110-120 V. Samples
were prepared for electrophoresis by the addition of 0.005% bromo-
phenol blue in 0.015 M Tris-HCl (pH 8.8). The standard molecular
weight markers used in these experiments were myosin (200,000),
phosphorylase b (94,000), bovine serum albumin (67,000), ovalbumin
(45,000), carbonic anhydrase (30,000), chymotrypsinogen (25,000),
soybean trypsin inhibitor (20,000), myoglobin (17,800), and cyto-
chrome c (12,400) (Sigma Chemical Co.). After electrophoresis, gels
were stained with Coomassie Blue (Serva Fine Biochemicals Inc.,
Garden City Park, NY) in 10% acetic acid:25% 2-propanol and
destained with a 10% acetic acid:25% 2-propanol solution. After
hydration, gels were dried and exposed to Kodak XAR-5 or XRP-1
X-ray film (Eastman Kodak Co., Rochester, NY) at -70'C for 2-6 or
7-21 d, respectively.
Efficiency of affinity labeling. To evaluate the efficiency of cross-
linking, '25I-Sm-C (1,500,000 cpm) was incubated with 1 ml of normal
human plasma and fractionated on a Sephadex G-200 column (see
below). Equivalent aliquots (100 Ml) were taken from the two peaks of
'251-SM-C that eluted with the plasma proteins (the y-globulin and the
near-albumin peaks) and subjected to SDS-PAGE either directly (un-
cross-linked) or after cross-linking with 1 mM DSS. Gels were fixed,
sliced into 2-mm fragments, and counted in a gamma counter
(Packard Instrument Co., Downers Grove, IL). Because free '251I-Sm-
C migrates as a single peak on the gel, and cross-linking decreases the
amount of free '251-Sm-C present in this peak by the amount cross-
linked, the efficiency of cross-linking was defined as number of counts
per minute lost from the peak of free '251I-Sm-C as a result of the cross-
linking procedure divided by the total number of counts per minute
present in the free '251I-Sm-C peak when the samples were not cross-
linked. Efficiencies of cross-linking were 1% in the y-globulin fractions
and 20% in the near-albumin fractions. Of the counts per minute
calculated to be cross-linked, >90% migrated in peaks representing
specific '25I-Sm-C binding proteins.
We also compared the number of counts per minute specifically
bound to Sm-C binding proteins in normal plasma by both a charcoal
binding assay (21) and by cross-linking with DSS. '251-Sm-C (100,000
cpm) was incubated with 5 ul of normal plasma in the absence and
presence of unlabeled Sm-C (25 ng), cross-linked with 1 mM DSS,
and subjected to SDS-PAGE. In parallel, 5 M1l of normal plasma was
incubated with 100,000 cpm 1251I-Sm-C and the apparent bound and
unbound counts per minute were separated with activated charcoal.
Although only 7.9% of the total counts per minute added were cross-
linked to bands representing specific Sm-C-binding-protein complexes,
these specifically bound counts per minute exceeded the counts per
minute that could be interpreted as bound in the charcoal binding
assay by about threefold (7,800 cpm vs. 2,200-2,600).
Chromatography. Gel filtration chromatography was performed
using a 1.6 X 90-cm (bed volume = 180 ml) Sephadex G-200 Superfine
(Pharmacia Fine Chemicals, Piscataway, NJ) column. Plasma samples
(0.5 ml) were eluted at 4VC in 0.1 M Na phosphate buffer (pH 7.2)
containing 0.01 M NaCl and collected in l-ml fractions which were
monitored for protein by determination of optical density at 280 nm.
Aliquots (200 ,ul) taken from selected column fractions (usually every
other) were affinity labeled with 1251-Sm-C (150,000 cpm) after chro-
matography in the presence or absence of unlabeled Sm-C as described
above, and subjected to SDS-PAGE. In other experiments, 0.5-ml
plasma samples were incubated with '251-Sm-C (60,000 cpm) before
chromatography. Fractions were counted in a gamma counter and
aliquots (50-100 ,ul) assayed to determine the migration of endogenous
immunoreactive Sm-C. In one experiment, a 0.5-ml sample of normal
plasma was affinity labeled with '251-Sm-C (2.5 X 106 cpm) in a total
volume of 5.0 ml before gel chromatography and 100-M1 aliquots from
selected fractions were subjected to SDS-PAGE. In another experiment,
4 ml of normal plasma was dialyzed against 0.1 M glycine-HCl, pH
3.6, for 72 h at room temperature before chromatography on a 2.6
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X 70-cm (bed volume = 372 ml) column equilibrated in 0.05 M
NaPO4, pH 7.4.
Concanavalin A (Con A)-Sepharose (Pharmacia Fine Chemicals)
affinity chromatography was performed on a 1.2 X 15-cm (bed volume
= 10 ml) column. Plasma samples (0.5 ml) were eluted at 4VC in 0.05
M Na phosphate buffer (pH 7.0) containing 0.1 M NaCl (40 ml). The
column was washed with an additional 40 ml of buffer, and the
adsorbed proteins were subsequently eluted in the starting buffer
containing 0.5 M a-methyl-D-mannoside (Sigma Chemical Co.). Ali-
quots (200 Al) from the Con A fractions were affinity labeled with 125I-
Sm-C (150,000 cpm) after chromatography in the presence or absence
of excess unlabeled Sm-C as described above. In other experiments,
plasma samples were affinity labeled with 1251-Sm-C (3 X 106 cpm)
before Con A fractionation.
Results
Affinity-labeled Sm-C binding-protein complexes
in whole plasma
When whole plasma samples were incubated with 1251I-Sm-C
and cross-linked, a number of specifically labeled Sm-C binding-
protein complexes were observed (Fig. 1 shows a representative
autoradiogram). In acromegalic plasmas, the most intensely
labeled complexes migrated as doublets with apparent Mr of
28,000-24,000 and 43,000-35,000. More faintly labeled com-
plexes were observed with apparent M, of 50,000, 80,000,
110,000, 135,000, and 160,000. In normal plasmas, the pattern
of specific '251I-Sm-C binding-protein was similar; however, the
labeling of the 28,000-24,000-mol wt doublets and the com-
plexes with M, of 80,000 and greater was less intense. The
43,000-35,000-mol wt complexes appeared as triplets and were
more intensely labeled than in the acromegalic samples. In
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Figure 1. Electrophoretic analysis and autoradiography of the specifi-
cally labeled Sm-C binding-protein complexes in acromegalic, nor-
mal, and hypopituitary whole plasma. Samples of each plasma were
affinity labeled with 1251-Sm-C in the absence (cold Sm-C, - in left
lane of each pair) or presence (cold Sm-C, + in right lane of each
pair) of excess unlabeled Sm-C as described in Methods. Arrowheads
indicate the bands that were abolished when the incubation was
performed in the presence of an excess of unlabeled Sm-C. In hypo-
pituitary plasma, arrowheads are omitted for the faintly labeled
135,000- and 28,000-24,000-mol wt bands, because these bands were
not invariably observed in such plasma. The vertical axis shows
molecular weights (X 10-3) of standards.
hypopituitary plasmas, the 28,000-24,000-mol wt doublets
and the complexes Mr of 80,000 and greater were either only
faintly visible or not observed. These plasmas exhibited the
most intensely labeled 43,000-35,000-mol wt complexes, which
again appeared as triplets. The 50,000-mol wt complexes were
somewhat less intensely labeled than in acromegalic and
normal plasma samples.
When the incubation of '25I-Sm-C and plasma was carried
out in the presence of an excess of unlabeled Sm-C, a number
of autoradiographic bands were neither abolished nor dimin-
ished in intensity. Bands near the bottom of all lanes (Mr of
14,000) probably represent dimers of the 1251-Sm-C molecule
resulting from the iodination procedure, because they were
also observed when '25I-Sm-C alone was subjected to SDS-
PAGE. Diffuse and noncompetitive labeling was observed in
the regions between 50,000 and 70,000 mol wt and between
135,000 and 160,000 mol wt (Figs. 1 and 2). Much of the
labeling in these areas apparently represented nonspecific
interaction of 125I-Sm-C and scavenger proteins because they
either appeared or increased in intensity when '25I-Sm-C
was displaced from its specific binding proteins by unla-
beled Sm-C.
Reduction of samples with 2% (3-mercaptoethanol prior to
SDS-PAGE did not alter the electrophoretic pattern of the
specifically labeled plasma Sm-C binding-protein complexes.
When whole plasma samples (diluted 1:10 in NaPO4 buffer,
pH 7.4) were heated at temperatures of up to 60°C for 20
min, the specific Sm-C binding proteins retained the capacity
to bind '251-Sm-C; however, temperatures of 65°C and greater
for 20 min destroyed the binding activity.
Inasmuch the GH secretory status of the blood donor
appeared to be an important determinant of which '251-Sm-C
binding-protein complexes were observed, the influence ofGH
secretory status was further studied. Plasma samples from
hypopituitary children obtained before and during human
growth hormone (hGH) treatment were affinity labeled and
subjected to SDS-PAGE (Fig. 2). In plasmas from untreated
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Figure 2. Electrophoretic analysis and autoradiography of the specifi-
cally labeled Sm-C binding-protein complexes in the whole plasma of
hypopituitary children before and during hGH treatment. Plasma
samples from hypopituitary children not receiving GH treatment (left
lane of each pair) and during hGH treatment (right lane of each pair)
were affinity labeled with '25I-Sm-C as described in Methods. Arrow-
heads indicate specific '251-Sm-C binding-protein complexes. Immu-
noreactive Sm-C concentrations for each plasma appear at the bot-
tom of the lanes. The vertical axis shows molecular weights (X l0-3)
of standards.
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GH-deficient children, an intensely labeled triplet complex
with an M. of 43,000-35,000 was consistently observed. In
samples from the same children obtained during hGH treat-
ment, the labeling intensity of the 43,000-35,000-mol wt
complex invariably diminished and, in most, faintly labeled
28,000-24,000-mol wt complexes were observed. The 160,000-,
135,000-, 110,000-, 80,000-, and 50,000-mol wt complexes
were not consistently affected.
Sm-C binding-protein complexes in fractionated plasma
Sephadex G-200 elution ofplasma incubated with '25I-Sm-C.
When acromegalic plasma was incubated with '251-Sm-C and
subjected to Sephadex G-200 chromatography, two major
peaks of '251I-Sm-C binding activity were observed (Fig. 3, see
vertical arrows). The first peak, which co-migrated with the
vast majority of the endogenous Sm-C, eluted in fractions
containing proteins slightly smaller than the y-globulin peak.
The second peak eluted from the column just after the albumin
peak. The migration of the '251I-Sm-C binding activity peaks,
as well as that of endogenous immunoreactive Sm-C, during
Sephadex G-200 fractionation of normal plasma was indistin-
guishable from acromegalic plasma (Fig. 4, vertical arrows).
In contrast, Sephadex chromatography revealed that hypopi-
tuitary plasma contained only a single peak of '251-Sm-C
binding activity, which eluted slightly after the albumin peak
and co-migrated with the endogenous Sm-C (Fig. 5, vertical
arrow).
Affinity-labeled 125ISmC binding-protein complexes in Se-
phadex G-200 fractions ofplasma. When acromegalic plasma
fractions eluting identically to the peaks of the '251-Sm-C
binding activity were affinity labeled, those eluting near the y-
globulin peak contained not only intensely labeled y-globulin-
sized bands (apparent M, of 160,000 and 135,000), but also
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Figure 4. Normal plasma affinity labeled with '251I-Sm-C before and
after Sephadex G-200 chromatography. Fresh plasma (0.5 ml) alone
and an equivalent volume of plasma affinity labeled with '251-Sm-C
before chromatography were fractionated, as described in Methods.
The protein profile, optical density of 280 nm, is displayed. Vertical
arrows at fractions 50 and 61 indicate the '251-Sm-C binding-activity
peaks observed when normal plasma was incubated with '251-Sm-C
before chromatography. The arrow at fraction 50 also denotes the
elution peak of immunoreactive Sm-C. Electrophoretic analysis and
autoradiography of representative fractions which were affinity la-
beled with '251-Sm-C before G-200 chromatography (top inset) or
after fractionation (bottom inset) appear as insets above the protein
profile. Horizontal arrowheads indicate the specifically labeled 1251I
Sm-C binding-protein complexes. Vertical axes on the right show












Figure 3. Sephadex G-200 fractionation of acromegalic plasma.
Plasma (0.5 ml) was fractionated on a 1.6 X 90-cm Sephadex G-200
Superfine column, as described in Methods. The protein profile, as
measured by optical density of 280 nm, is displayed. Vertical arrows
at fractions 51 and 63 indicate the peaks of 1251-Sm-C binding
activity observed when plasma was incubated with 1251-Sm-C before
Sephadex chromatography. The arrow at fraction 51 also denotes the
elution peak of immunoreactive Sm-C. Electrophoretic analysis and
autoradiography of representative fractions appear in the inset above
the protein profile. Horizontal arrowheads indicate the bands that
were abolished in the presence of an excess of unlabeled Sm-C (lanes
not shown), i.e., specifically labeled Sm-C binding-protein complexes.
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Figure 5. Sephadex G-200 fractionation of hypopituitary plasma.
Plasma (0.5 ml) was fractionated as described in Methods. The
protein profile, optical density of 280 nm, is displayed. The vertical
arrow at fraction 63 indicates the peak of '25I-Sm-C binding activity
observed when plasma was incubated with labeled Sm-C before Se-
phadex chromatography. Electrophoretic analysis and autoradiogra-
phy of representative fractions appears in the inset above the protein
profile. Horizontal arrowheads indicate the specifically labeled bands.
The vertical axis shows molecular weights (XI 0-s) of standards.









'25I-Sm-C binding-protein complexes with apparent Mr of
110,000, 80,000, 50,000, 43,000-35,000, and 24,000 (Fig. 3).
Of these complexes, the 160,000-, 50,000-, and 24,000-mol wt
species were the most intensely labeled. The smaller complexes,
i.e., the 50,000-, 43,000-35,000-, and 24,000-mol wt species,
were also observed in size-appropriate column fractions (i.e.,
their migration during gel filtration was consistent with their
apparent Mr as determined by SDS-PAGE) and account for
the second peak of '25I-Sm-C binding activity. The 50,000-
and 24,000-mol wt species had two distinct peaks of labeling
intensity which were coincident with the 251I-Sm-C binding
activity peaks (Fig. 3, insets; contrast the labeling intensity of
these species in fractions 51 and 64 with their labeling in
fraction 58). On the other hand, the 43,000-35,000-mol wt
species eluted as a broad peak with the most intense labeling
occurring near the albumin peak (Fig. 3, insets; note the
similar labeling intensity of the 43,000-35,000-mol wt species
in fractions 51, 58 and 64; fractions 60-62, not shown,
contained the most intensely labeled 43,000-35,000-mol wt
species).
When normal plasma was fractionated, the elution pattern
of the specific Sm-C binding-protein complexes was similar to
that of acromegalic plasma (Fig. 4, insets; affinity labeled after
G-200 chromatography). However, in normal plasma labeled
43,000-35,000-mol wt complexes were nearly absent in frac-
tions from the peak of 1251I-Sm-C binding activity eluting near
y-globulin, but were intensely labeled in fractions eluting just
after the albumin peak. Together with the 50,000- and 24,000-
mol wt species, these binding proteins appear to account for
the second peak of '25I-Sm-C binding activity observed in both
acromegalic and normal plasma. That a portion of the 43,000-
35,000-mol wt binding species eluted with the -y-globulin-sized
binding proteins in acromegalic plasma is not readily apparent,
but may be due to nonspecific protein-protein associations.
The single 1251I-Sm-C binding activity peak of hypopituitary
plasma that eluted slightly after albumin contained intensely
labeled 43,000-35,000-mol wt complexes and very faintly
labeled bands representing the 50,000- and 24,000-mol wt
complexes (Fig. 5). The higher molecular weight '251-Sm-C
binding-protein complexes present in the -y-globulin fractions
of both acromegalic and normal plasma were not observed in
hypopituitary plasma; however, very faintly labeled 50,000-
and 24,000-mol wt complexes were detected in these fractions.
Because all labeled Sm-C binding-protein complexes did
not migrate in a size-appropriate fashion during Sephadex
G-200 column chromatography, normal plasma was affinity
labeled before Sephadex G-200 chromatography to determine
if the affinity-labeled complexes migrate aberrantly under these
conditions as well. Cross-linked '251I-Sm-C binding-protein
complexes eluted predominantly in size-appropriate Sephadex
column fractions (Fig. 4, top inset: affinity labeled before G-
200 chromatography); specifically, 'y-globulin-sized column
fractions contained only very faint bands of <80,000-mol wt
cross-linked complexes. These results imply that cross-linked
'251-Sm-C binding-protein complexes do not migrate aberrantly
on Sephadex G-200 columns. In addition, these results suggest
that covalent cross-linking of each entity comprising the
160,000-mol wt complex is necessary for this complex to
remain intact during SDS electrophoresis. SDS-PAGE may
not by itself, however, account for the <80,000-mol wt com-
plexes observed in y-globulin-sized column fractions, in that
events occurring during or after column chromatography, but
before cross-linking, such as dilution or proteolysis, could
result in the dissociation of the 160,000-mol wt complex.
Because Sm-C binding proteins can be freed of the bound
peptide by acidification, normal plasma was incubated in 0.1
M glycine-HCl, pH 3.6 (ionic strength 0.05) (20) and then
subjected to Sephadex G-200 chromatography under neutral
conditions (Fig. 6). Acidification resulted in the apparent
elimination of the specifically labeled Sm-C binding-protein
complexes with Mr greater than or equal to 50,000, i.e., those
complexes which previously eluted with the y-globulin peak.
Acid treatment also resulted in an apparent increase in non-
specific binding of 1251I-Sm-C, particularly in the proteins with
Mr > 100,000 (see Fig. 6, inset at fraction 90, for example).
The specific binding activity of the 43,000-35,000- and 28,000-
24,000-mol wt complexes was preserved. The 43,000-35,000-
mol wt complexes eluted in a narrow peak immediately after
albumin. These complexes, which had appeared as a triplet
when nonacid-treated plasma was studied, now appeared on
autoradiograms as a broad band with M, of 45,000-30,000,
suggesting that they had sustained some damage as a result of
acidification. After acid treatment, the 28,000-24,000-mol wt
band, which had eluted in two distinct peaks in nonacid-
treated plasma (both with the y-globulin-sized proteins and in
size-appropriate fractions), appeared as a single broad, size-
appropriate peak whose labeling intensity was markedly in-
creased. As expected, the immunoreactive Sm-C eluted as the
free peptide.
Con A-Sepharose fractionation of affinity-labeled '25I-Sm-
C binding-protein complexes. Con A-Sepharose column chro-
matography effects a fractionation of the specific plasma Sm-
..-
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Figure 6. Acid-treated normal plasma affinity labeled with '251-Sm-C
after G-200 chromatography. Normal plasma was dialyzed for 72 h
at 220C against 6 liters of 0.1 M glycine-HCI, pH 3.6, and subjected
to Sephadex G-200 chromatography in 0.05 M NaPO4, pH 7.4, as
described in Methods. Closed circles and solid lines represent the
protein profile (optical density of 280 nm) and open squares and the
dotted line represent the elution profile of immunoreactive Sm-C.
Electrophoretic analysis and autoradiography of representative frac-
tions that were affinity labeled with '25I-Sm-C after chromatography
appear in the inset above. Horizontal arrowheads indicate the specifi-
cally labeled GH-dependent 24,000-mol wt complex. The vertical
axis on the right shows molecular weights (XI0-3) of standards.
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C binding-protein complexes, which is unchanged when cross-
linking is performed before chromatography (Fig. 7). In all
plasmas studied, the fall-through (i.e., nonadsorbed) fraction
contained only the 43,000-35,000-mol wt Sm-C binding-
protein complexes. In contrast, when acromegalic or normal
plasma were chromatographed, the retentate fraction (i.e., the
fraction eluted from the column with 0.5 M a-methyl-D-
mannoside) contained all of the previously observed specific
Sm-C binding-protein complexes (160,000, 135,000, 110,000,
80,000, 50,000, 43,000-35,000, and 28,000-24,000 mol wt).
The 43,000-35,000-mol wt species, however, were faintly
labeled compared with their labeling in the fall-through fraction.
The Con A retentate fractions of hypopituitary plasma
contained only faintly labeled 43,000-35,000-mol wt complexes.
Thus, affinity for Con A distinguishes the 43,000-35,000-mol
wt species from other Sm-C binding-protein complexes. That
some of the 43,000-35,000-mol wt species were observed in
the retentate fractions was attributed to inefficient fractionation
due to nonspecific interactions among proteins.
Table I. Characteristics ofAffinity-labeled J2SI-Sm-C
Binding-Protein Complexes in Human Plasma
Elutes with
GH -y-globulin on Affinity for
MW* dependentt Sephadex G-200§ Con-A"
160,000 + + +
135,000 + + +
110,000 + + +
80,000 + + +
50,000 + + +
43,000-35,000 - -
28,000-24,000 + + +
* Apparent M, determined on SDS-PAGE.
t Labeling is more intense in acromegalic than normal whole plasma,
but faint or absent in hypopituitary plasma.
§ Identified in fractions migrating near y-globulin when acromegalic
or normal plasma is eluted.
11 Retained by a Con A-Sepharose affinity column.
Discussion
Specific Sm-C binding-protein complexes have been identified
in human plasma by affinity labeling with '25I-Sm-C using the
homobifunctional cross-linking agent DSS and separating the
products by SDS-PAGE. These complexes can be distinguished
from each other by several criteria: apparent Mr, GH depen-
dence, behavior on Sephadex G-200, and affinity for Con A-
Sepharose (Table I).
Consistent with the findings of others (6-11, 16-19), our
observations suggest that two types of circulating somatomedin
binding proteins can be distinguished on the basis of their GH
dependence. A GH-dependent somatomedin binding protein
has been shown to elute near the y-globulin peak during gel
filtration chromatography (6-11, 16, 18, 19). In these column
fractions from either acromegalic or normal plasma, we ob-
served not only specific 1251I-Sm-C binding-protein complexes
similar in size to y-globulin (apparent M, of 160,000 and
135,000), but also smaller complexes with apparent M, of
110,000, 80,000, 50,000, and 28,000-24,000. These complexes
account for the GH-dependent y-globulin peak of 125I-Sm-C
binding activity inasmuch as identical column fractions from
200 Figure 7. Electrophoretic anal-
ysis and autoradiography of
:2I-Sm-C affinity-labeled nor-
mal plasma fractionated by
_ 94 Con A-Sepharose chromatogra-
6 phy. Whole plasma was affinity
labeled and fractionated by
Con A-Sepharose, as described
45 in Methods. Fall through refers
r/ fl/ to the column void volume
7 9/ that contained proteins not ad-
/, _ 30 sorbed by Con-A. Retentate re-/ fers to the fraction that was
eluted from the column using20 0.5 M a-methyl-mannoside
and contained the proteins ad-
*- _ sorbed by Con A. Arrows indi-
RETENTATE FALL THROUGH cate specifically labeled Sm-C
binding-protein complexes. The vertical axis on the left shows molec-
ular weights (X 10-3) of standards.
hypopituitary plasmas contained either no specifically labeled
complexes or only faintly labeled representatives of the 50,000
and 28,000-24,000-mol wt species. The relative labeling inten-
sity of each of these complexes in acromegalic, normal, and
hypopituitary whole plasma (more intense labeling in acro-
megalic than normal plasma, and either faint or no labeling
in hypopituitary plasma) and the finding that some of these
complexes appear in the plasma of hypopituitary children
undergoing GH therapy provides strong evidence of their GH
dependency. On the other hand, the 43,000-35,000-mol wt
125I-Sm-C binding-protein complexes did not appear to be GH
dependent, in that they were present in all plasma samples
regardless of the GH status of the donor. These complexes
generally eluted slightly after the albumin peak during gel
filtration and did not appear to be associated with the GH-
dependent complexes that migrated near the y-globulin peak.
The 43,000-35,000-mol wt complexes account for the non-
GH dependent 1251-Sm-C binding activity reported by others
(6-11), but in normal and acromegalic plasma the 50,000-
and 28,000-24,000-mol wt GH-dependent binding species also
contribute to this binding peak. In addition, we were able to
separate the two types of Sm-C binding proteins by Con A
affinity chromatography. The GH-dependent Sm-C binding
complexes (i.e., 160,000, 135,000, 110,000, 80,000, 50,000,
and 28,000-24,000 mol wt) were adsorbed by Con A, whereas
the non-GH-dependent species (43,000-35,000 mol wt) eluted
in the void volume.
Affinity labeling of specific Sm-C binding-protein complexes
is by definition reduced or abolished in the presence of
sufficiently high concentrations of unlabeled Sm-C because the
binding of '251-Sm-C to these proteins is largely determined by
binding site occupancy. We observed that concentrations of
unlabeled Sm-C in the range of those found in plasma (na-
nomolar) consistently reduce the labeling intensity of all
specific '251I-Sm-C binding-protein complexes. This suggests
that endogenous plasma Sm-C concentrations influence the
labeling intensity of specific binding complexes.
The labeling intensity of the 43,000-35,000-mol wt species
is inversely proportional to the plasma Sm-C concentration of
the blood donor, i.e., most intense in hypopituitary plasma
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and least intense in acromegalic plasma. Furthermore, there is
a marked decrease in their labeling intensity after plasma Sm-
C concentrations are normalized in hypopituitary children by
GH treatment. Nonetheless, the 43,000-35,000-mol wt com-
plexes are intensely labeled in all plasmas studied, suggesting
that these species are relatively unsaturated regardless of plasma
Sm-C concentrations. This concept is supported by the obser-
vations that only a small portion of the endogenous somato-
medin migrates with the 43,000-35,000-mol wt species during
gel chromatography (6-10, 13, 18, 19), but when '25I-Sm-C is
incubated with normal plasma prior to chromatography, the
majority of the bound label elutes in the 43,000-35,000 mol
wt range.
Consistent with our findings and those of others (5-7, 13,
20, 21), Furlanetto (8) has reported that 95% of the immuno-
reactive Sm-C in normal serum is associated with GH-depen-
dent, y-globulin-sized binding activity that is adsorbed by Con
A-Sepharose. That the majority of endogenous Sm-C is asso-
ciated with the GH-dependent binding species strongly suggests
that these proteins have a higher affinity for Sm-C than the
non-GH-dependent species. This is also consistent with the
findings of Binoux et al. (12), who reported that human serum
contains two binding proteins that exhibit different affinities
for the somatomedins: one exhibiting a higher affinity for Sm-
C/IGF-I was the predominant binding species in the 100,000-
170,000 mol wt range, whereas a binding protein with a
selective affinity for IGF-II predominated in the 40,000-70,000
mol wt range. Confirmation of this hypothesis will require
competition studies using homogeneous preparations of the
different binding proteins.
There are some problems inherent in studies that employ
chemical cross-linking agents (28). Because DSS can covalently
cross-link any two free amino groups in the proper orientation
and within an 11 A radius, nonspecific bands resulting from
random protein-protein interactions and those representing
'25I-Sm-C bound to scavenger proteins (e.g., albumin) were
consistently observed, especially after acid treatment of plasma.
That the specifically labeled binding proteins with M, of
<50,000 often appeared as doublet or triplet bands may
represent an additional problem of this methodology. Because
the observed bands represent the Mr of a binding protein plus
the cross-linked 1251I-labeled moiety, the 28,000-24,000-mol wt
doublet may represent the resolution of a single binding
protein cross-linked to intact '251-Sm-C molecules and to 1251.
labeled fragments of Sm-C molecules. Svoboda et al. (29) have
reported that the purified Sm-C peptide can undergo autolysis,
which results in fragments with nearly identical molecular
weights (3,000-4,000). On the other hand, the 43,000-35,000-
mol wt triplet bands clearly represent a more complicated
situation. The appearance of triplet bands could be the result
of a combination of factors, such as intact 125I-Sm-C molecule(s)
and '251I-labeled fragment(s) of Sm-C molecules cross-linked to
a single binding protein and/or to binding proteins that had
been modified by glycosylation or proteolysis. Alternatively,
these replicate bands could represent unique binding proteins
with similar molecular weights.
Using the same affinity-labeling technique, we have previ-
ously examined serum Sm-C binding proteins in the rat (23)
and found that they bear remarkable similarity to those
observed in human plasma. Normal rat sera exhibited Sm-C
binding species with Mr of 95,000, 26,000-23,000, and possibly
a series of complexes ranging from 175,000 to 115,000, none
of which were observed in hypophysectomized rat sera. These
complexes are analogous to the GH-dependent Sm-C binding
proteins in human plasma. Hypophysectomized rat serum
contained only a 36,000-33,000-mol wt doublet, which appears
homologous to the 43,000-35,000-mol wt non-GH-dependent
species observed in human plasma. Using an alternative cross-
linking procedure (30), Schwander et al. (31) have reported a
35,000-mol wt IGF-I binding protein in rat liver perfusates,
whereas Hossenlopp et al. (32) reported an IGF-I binding
protein in both cultured rat and human liver media which
migrated as doublet bands between 37,000 and 40,000 mol
wt. A multiplication-stimulating activity carrier protein of
similar size has been purified from conditioned media of the
rat liver cell line, BRL-3A, by Knauer et al. (33). In addition,
we have also observed affinity-labeled complexes with apparent
Mr of 45,000-35,000 in human cord plasma and amniotic
fluid (22).
In the present study, we consistently labeled multiple Sm-
C binding proteins (complexes with apparent Mr of 160,000,
135,000, 110,000, 80,000, 50,000, and 28,000-24,000) in
fractions that elute near the 'y-globulin peak during G-200
Sephadex chromatography. These observations indicate that
each of these species is in some way associated with the y-
globulin-sized, GH-dependent '25I-Sm-C binding activity. In-
deed, the co-migration of the 160,000-mol wt complex and
the smaller species strongly suggests that the native -y-globulin-
sized binding protein is a complex that dissociates to generate
the pattern of labeled species we have observed on SDS gels.
It is not clear whether the 1 60,000-mol wt complex dissociates
as a result of instability in a dilute solution (i.e., dissociation
during and after chromatography but before cross-linking) or
as a consequence of the SDS treatment followed by electro-
phoretic separation. These two possibilities are, of course, not
mutually exclusive, and we suspect that both occur. The
finding that the <160,000-mol wt complexes migrated pre-
dominately in size-appropriate column fractions when plasma
was labeled before G-200 chromatography suggests that these
complexes circulate free in plasma. It seems possible, therefore,
that an equilibrium exists in plasma between the 160,000-mol
wt complex and the smaller binding species, such that dilution
during column chromatography favors a dissociation of the
1 60,000-mol wt complex into its constituent subunits, as
previously suggested by Daughaday et al. (13). Dissociation of
subunits could also expose more Sm-C/IGF-I binding sites
and, thus, explain the increased binding in the y-globulin
fractions of chromatographed human serum observed by White
et al. (19) when they studied binding after elution.
Many studies have documented that acidification of plasma
effects a dissociation of Sm-C and its binding proteins (3, 5,
6, 8, 17, 20, 21). Our data, like those of others (8, 18, 33),
indicate that acidification dissociates the GH-dependent Sm-C
binding protein into subunits. After acidification, normal
plasma exhibited only two specific Sm-C binding-protein com-
plexes: the non-GH-dependent 43,000-35,000-mol wt complex
and the GH-dependent 28,000-24,000-mol wt species. The
migration of the 43,000-35,000-mol wt complex during Se-
phadex G-200 chromatography was essentially unchanged by
acidification, although the diffuse labeling of these complexes
indicates that they may be unstable under acidic conditions.
On the other hand, the 28,000-24,000-mol wt complex eluted
in size-appropriate fractions as a single broad peak. The acid-
mediated destruction of the y-globulin-sized Sm-C binding
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protein complex and the concurrent increase in the labeling
intensity of the 28,000-24,000-mol wt complexes suggests that
the 28,000-24,000-mol wt complex is the Sm-C binding subunit
of the 160,000-mol wt, GH-dependent binding-protein complex.
Furlanetto (8) has suggested that the 160,000-mol wt Sm-
C binding protein is composed of at least two GH-dependent
subunits, one of which does not bind Sm-C. Inasmuch our
technique only allows visualization of proteins which are
directly associated with '251-Sm-C, our findings do not preclude
this possibility; however, they do suggest an alternative hy-
pothesis. In fractions eluting from Sephadex G-200 columns
with y-globulin-sized proteins and in the retentate fractions of
Con A columns, the specifically labeled '251I-Sm-C binding-
protein complexes consistently appeared in near multiples of
28,000-24,000 mol wt. This observation suggests that the
160,000-mol wt Sm-C binding-protein complex may be an
oligomer composed of noncovalently linked 28,000-24,000-
mol wt subunits. The occurrence of six GH-dependent binding
species suggests that the native 160,000-mol wt complex is a
hexamer and that each of the smaller species represents an
oligomer composed of a different number of 28,000-24,000-
mol wt protomers covalently cross-linked to one another by
DSS. This argument is supported by studies of Davies and
Stark (34), who demonstrated that cross-linked oligomers
composed of identical subunits can be resolved on SDS
polyacrylamide gels to a set of species with molecular weights
equal to integral multiples of the protomer's molecular weight.
Using DMS to study subunit structure of oligomeric proteins,
they clearly showed that the number of principal species
observed is identical to the number of protomers in the native
oligomer.
The 28,000-24,000-, 50,000-, and 160,000-mol wt com-
plexes that we observed were consistently the most intensely
labeled binding proteins eluting in the 'v-globulin-sized peak
of '25I-Sm-C binding activity, while the 110,000- and 80,000-
mol wt species in the same fractions were often only faintly
labeled. The precise reason(s) for the differences in labeling
intensity among the putative oligomers is unknown. One cause
may be the ineffectiveness of DSS in cross-linking protomers
that are arranged in certain conformations. For example, some
protomers, or the 1251-Sm-C molecules they bind, may not be
accessible for cross-linking, resulting in complexes with aggre-
gated but uncross-linked protomers or in complexes not co-
valently crosslinked to 1251-Sm-C. It has been suggested that a
portion of the circulating immunoreactive Sm-C is unavailable
for the antibody/antigen reaction because of the manner in
which it is complexed with binding proteins (20, 21). Perhaps
the same factors that prevent the detection of immunoreactive
Sm-C could also prevent cross-linking of the binding protein
in certain steric arrangements. This could in turn affect labeling
intensity. Another explanation for the labeling differences
among the GH-dependent binding species may be that certain
complexes, as the 110,000- and 80,000-mol wt species, are
intrinsically unstable or labile intermediate forms of the
160,000-mol wt GH dependent complex. Alternatively, each
complex may have a unique affinity for Sm-C.
Although consistent with all our findings, our conclusions
as to the composition of the GH-dependent, '-globulin-sized
Sm-C binding protein remain speculative. Alternative hy-
potheses are that the GH-dependent complexes we observed
are the result of partial proteolysis of the native 160,000-mol
wt binding protein or that each represents a unique binding
protein induced by GH. In future experiments, we will attempt
to demonstrate involvement of the 28,000-24,000-mol wt
subunit in the native 160,000-mol wt Sm-C binding-protein
complex by immunologic means.
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